Frontiers in Neurology (Oct 2015)

The central biobank and virtual biobank of BIOMARKAPD: a resource for studies on neurodegenerative diseases

  • Babette eReijs,
  • Charlotte Elisabeth Teunissen,
  • Nikolai eGoncharenko,
  • Fay eBetsou,
  • Kaj eBlennow,
  • Inês eBaldeiras,
  • Frederic eBrosseron,
  • Enrica eCavedo,
  • Tormod eFladby,
  • Lutz eFroelich,
  • Tomasz eGabryelewicz,
  • Hakan eGurvit,
  • Elisabeth eKapaki,
  • Peter eKoson,
  • Luka eKulic,
  • Sylvain eLehmann,
  • Piotr eLewczuk,
  • Alberto eLleó,
  • Walter eMaetzler,
  • Alexandre ede Mendonça,
  • Anne-Marie eMiller,
  • José Luis eMolinuevo,
  • Brit eMollenhauer,
  • Lucilla eParnetti,
  • Uros eRot,
  • Anja eSchneider,
  • Anja Hviid Simonsen,
  • Fabrizio eTagliavini,
  • Magda eTsolaki,
  • Marcel M Verbeek,
  • Marzena eZboch,
  • Frans R Verhey,
  • Bengt eWinblad,
  • Philip eScheltens,
  • Henrik eZetterberg,
  • Pieter Jelle eVisser,
  • Pieter Jelle eVisser

DOI
https://doi.org/10.3389/fneur.2015.00216
Journal volume & issue
Vol. 6

Abstract

Read online

AbstractBiobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's Disease (BIOMARKAPD) is a European multicenter study, funded by the EU Joint Programme - Neurodegenerative Disease Research (JPND), that aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer’s disease (AD) and Parkinson’s disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized preanalytical procedures (SOP) and stored at Integrated BioBank of Luxembourg (IBBL). The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia (VaD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), PD, PD with dementia, and dementia with Lewy bodies (DLB). The virtual biobank contains information on over 8600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank.

Keywords